Prediction of the Virological Response to Etravirine in Clinical Practice: Comparison of Three Genotype Algorithms

被引:15
作者
Cotte, Laurent [1 ,2 ,3 ]
Trabaud, Mary-Anne [4 ]
Tardy, Jean-Claude [4 ]
Brochier, Corinne [1 ,2 ]
Gilibert, Rene-Pierre [4 ]
Miailhes, Patrick [1 ,2 ,3 ]
Trepo, Christian [1 ,2 ,3 ,5 ]
Andre, Patrice [4 ,6 ,7 ]
机构
[1] Hosp Civils Lyon, Hotel Dieu, Serv Hepatol, F-69002 Lyon, France
[2] Hosp Civils Lyon, Hotel Dieu, SIDA, F-69002 Lyon, France
[3] INSERM, U871, F-69008 Lyon, France
[4] Hosp Civils Lyon, Lab Virol Nord, F-69002 Lyon, France
[5] Univ Lyon 1, Lyon Est IFR62, F-69365 Lyon, France
[6] INSERM, U851, F-69008 Lyon, France
[7] Univ Lyon 1, Biosci Lyon Gerland IFR128, F-69365 Lyon, France
关键词
etravirine; HIV-1; NNRTI; resistance algorithm; EXPERIENCED HIV-1-INFECTED PATIENTS; PLACEBO-CONTROLLED TRIAL; TMC125; ETRAVIRINE; DOUBLE-BLIND; RESISTANCE; EFFICACY; SAFETY; DUET-2;
D O I
10.1002/jmv.21461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The current Agence Nationale de Recherche sur le SIDA (ANRS)/International AIDS Society (IAS) algorithm predicts resistance to etravirine for viruses harboring >= 3 mutations from a list of 13 reverse transcriptase (RT) mutations. Two weighted algorithms, best correlated with fold changes to etravirine, have been described recently. A retrospective virological analysis of a major French city HIV sequences database was undertaken to assess the proportion of etravirine resistant viruses according to these three algorithms and the correlations between them. Two thousand six hundred eighty FIT sequences were analyzed, including 749 from naive patients and 926 from patients previously treated with non-nucleoside reverse transcriptase inhibitor (NNRTI). Combinations of mutations associated with etravirine resistance according to the three algorithms were found in 0%, 2.3%, and 3.6% of naive patients, and in 2.4%, 20.4%, and 19.3% of patients previously treated with NNRTIs. Concordance between the algorithms was weak (2 x 2 Kendall's tau: 0.787, 0.395, and 0.584). Most of the discordance was due to the differential weights attributed to Y181C/V, L1001, and K101P in the two weighted algorithms. It is concluded that the current ANRS/ IAS algorithm probably underestimates the proportion of viruses partially resistant to etravirine in NNRTI-experienced patients. Improvements in algorithms are needed to take into account the partial resistance associated with some mutation patterns, and should include either additional mutations to the current list and/or differential weights for specific mutations. Surveys of naive patients should be conducted to estimate the risk of primary resistance to etravirine in a minority of cases. J. Med. Virol. 81:672-677, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:672 / 677
页数:6
相关论文
共 12 条
[1]   TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].
Andries, K ;
Azijn, H ;
Thielemans, T ;
Ludovici, D ;
Kukla, M ;
Heeres, J ;
Janssen, P ;
De Corte, B ;
Vingerhoets, J ;
Pauwels, R ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686
[2]  
BENHAMIDA J, 2008, ANTIVIR THER, V13, pS3
[3]  
*FRENCH ANRS AC11, 2008, HIV 1 GEN DRUG RES I, V17
[4]   Shifting paradigms: the resistance profile of etravirine [J].
Geretti, Anna Maria .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (04) :643-647
[5]  
Johnson Victoria A, 2008, Top HIV Med, V16, P62
[6]   Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial [J].
Lazzarin, Adriano ;
Campbell, Thomas ;
Clotet, Bonaventura ;
Johnson, Margaret ;
Katlama, Christine ;
Moll, Arend ;
Towner, William ;
Trortier, Benoit ;
Peeters, Monika ;
Vingerhoets, Johan ;
de Smedt, Goedele ;
Baeten, Benny ;
Beets, Greet ;
Sinha, Rekha ;
Woodfall, Brian .
LANCET, 2007, 370 (9581) :39-48
[7]   Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial [J].
Madruga, Jose Valdez ;
Cahn, Pedro ;
Grinsztejn, Beatriz ;
Haubrich, Richard ;
Lalezari, Jacob ;
Mills, Anthony ;
Pialoux, Gilles ;
Wilkin, Timothy ;
Peeters, Monika ;
Vingerhoets, Johan ;
de Smedt, Goedele ;
Leopold, Lorant ;
Trefiglio, Roberto ;
Woodfall, Brion .
LANCET, 2007, 370 (9581) :29-38
[8]  
PICCHIO G, 2008, ANTIVIR THER, V13, pS3
[9]  
Schapiro J, 2008, 6 EUR HIV DRUG RES W
[10]  
Vingerhoets J, 2007, ANTIVIR THER, V12, pS34